4.6 Editorial Material

The increasing complexity of the core outcomes landscape

Journal

JOURNAL OF CLINICAL EPIDEMIOLOGY
Volume 116, Issue -, Pages 150-154

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jclinepi.2019.05.016

Keywords

Core outcomes; core outcome sets; COS; Standardized outcome sets

Funding

  1. Amgen
  2. Genentech
  3. Johnson Johnson
  4. Merck
  5. OMERACT (Outcomes Measure in Rheumatology)
  6. Pfizer
  7. UCB

Ask authors/readers for more resources

In this project, we set out to identify ways to increase the uptake of core outcome sets in clinical research. In doing so, we uncovered a growing recognition, across many different health care sectors, of the need for common, relevant outcomes to improve the quality of decision-making. This has led to a plethora of projects, initiatives, and new organizations all intended to develop standardized outcomes and outcome measures for their particular fields. However, the standardized outcome sets developed across siloed initiatives do not carry over to other sectors, such as from research to quality of care. This trend has the potential to lead to confusion and unintended redundancies, as well as wasteful use of both financial and intellectual resources. Better communication and collaboration among different initiatives, and more deliberate alignments of initiative scopes, are needed to ensure a future paradigm in which standards align across contexts where possible and differ for understandable and transparent reasons. (C) 2019 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available